Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Authors

Lucinda Jane Billingham (ORCID: https://orcid.org/0000-0001-8581-4262)
Penella J. Woll (ORCID: https://orcid.org/0000-0002-1118-0831)
Amanda Kirkham (ORCID: https://orcid.org/0000-0002-2593-7970)
Joshua Savage (ORCID: https://orcid.org/0000-0003-0599-0245)
Charlotte Gaskell (ORCID: https://orcid.org/0000-0002-6382-2277)
David H. Dockrell (ORCID: https://orcid.org/0000-0002-2718-4861)
S. Westwell
Sadie Johnson (ORCID: https://orcid.org/0000-0001-5250-9835)
Mark Bower (ORCID: https://orcid.org/0000-0002-4077-6351)
Martin J. Leahy (ORCID: https://orcid.org/0000-0003-1558-4574)
Christine Bowman
Robin Young

Institutions

Sheffield Teaching Hospitals NHS Foundation Trust (GB)
The Christie NHS Foundation Trust (GB)
Cancer Research UK Clinical Trials Unit (GB)
Chelsea and Westminster Hospital (GB)
University Hospitals Sussex NHS Foundation Trust (GB)
Centre for Inflammation Research (GB)
University of Birmingham (GB)
University of Sheffield (GB)
University of Edinburgh (GB)

Publication Details

Journal: BMC Cancer
Published: 2025-03-19
DOI: https://doi.org/10.1186/s12885-025-13890-x
Primary Topic: Viral-associated cancers and disorders
Type: article
Field-Weighted Citation Impact: 0.00

Funders

AstraZeneca
Cancer Research UK
University of Sheffield
European Society for Medical Oncology
Sheffield Teaching Hospitals NHS Foundation Trust
Imperial Experimental Cancer Medicine Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Lucinda Jane Billingham, Penella J. Woll, Amanda Kirkham, Joshua Savage et al.

Mar 19, 2025

BMC Cancer

Viral-associated cancers and disorders

article

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

Lucinda Jane Billingham, Penella J. Woll, Amanda Kirkham, Joshua Savage, Charlotte Gaskell, David H. Dockrell, S. Westwell, Sadie Johnson, Mark Bower, Martin J. Leahy, Christine Bowman, Robin Young

March 19, 2025article en

Abstract

No abstract available for this paper.

BMC CancerVol. 25(1)

Sheffield Teaching Hospitals NHS Foundation Trust (GB), The Christie NHS Foundation Trust (GB), Cancer Research UK Clinical Trials Unit (GB), Chelsea and Westminster Hospital (GB), University Hospitals Sussex NHS Foundation Trust (GB), Centre for Inflammation Research (GB), University of Birmingham (GB), University of Sheffield (GB), University of Edinburgh (GB)

AstraZeneca, Cancer Research UK, University of Sheffield, European Society for Medical Oncology, Sheffield Teaching Hospitals NHS Foundation Trust, Imperial Experimental Cancer Medicine Centre

Good health and well-being

Openalex Percentile: Top 93%

Viral-associated cancers and disorders

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial — Lucinda Jane Billingham, Penella J. Woll, et al. · BMC Cancer (2025) | TGRS Research Map | TGRS